My Market Wizard

AMICUS THERAPEUTICS, INC. 8-K Analysis & Summary – 2/21/2025

⚠️This is not investment advice.

⚠️ This is an experimental project and this report is for informational purposes only and should not be considered investment advice. Conduct your own thorough research and consult with a qualified financial advisor before making any investment decisions. ⚠️

Amicus Therapeutics, Inc.

Filing date:

02/21/2025

TLDR:

Amicus Therapeutics, Inc. filed a prospectus supplement to register remaining unsold shares of common stock under its existing at-the-market program.

ELI5:

Amicus Therapeutics is selling more of its stock, and this report includes a legal opinion about the stock sale.

Accession #:

0001104659-25-016127

Published on

Analyst Summary

  • Amicus Therapeutics, Inc. filed a prospectus supplement on February 21, 2025, registering remaining unsold shares of common stock.
  • The shares are being sold under the company’s existing at-the-market program established on November 7, 2022.
  • Troutman Pepper Locke LLP provided a legal opinion regarding the legality of the shares of common stock.
  • The company may issue up to $164,206,529 of shares of Common Stock.

⚠️ This is an experimental project and this report is for informational purposes only and should not be considered investment advice. Conduct your own thorough research and consult with a qualified financial advisor before making any investment decisions. ⚠️